benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide has been researched along with losartan potassium in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, CWC; Dong, TTX; Liu, EYL; Luk, WKW; Tsim, KWK; Wu, KQY; Xu, ML; Yao, P | 1 |
1 other study(ies) available for benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide and losartan potassium
| Article | Year |
|---|---|
Erythropoietin regulates the expression of dimeric form of acetylcholinesterase during differentiation of erythroblast.
Topics: Acetylcholinesterase; Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide; Cell Differentiation; Cell Line; Chromatin Immunoprecipitation; Chromones; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythroblasts; Erythropoietin; GATA1 Transcription Factor; Gene Expression; Gene Expression Regulation; Humans; Membrane Lipids; Morpholines; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Messenger; Signal Transduction; Time Factors; Transfection | 2018 |